诺和诺德与Deep Apple联手成立减肥口服药物研发联盟-动脉网

Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

benzinga 等信源发布 2025-06-11 10:40



可切换为仅中文







Deep Apple Therapeutics, Inc.

深苹果治疗学公司

announced on Wednesday a research collaboration and exclusive worldwide license agreement with

周三宣布了一项研究合作和全球独家许可协议

Novo Nordisk A/S

诺和诺德公司

NVO

新活力组织 (NVO)

to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases,

发现、开发和商业化针对一种新型非肠促胰岛素GPCR靶点的口服小分子治疗药物，用于心代谢疾病，

including obesity

包括肥胖症

。

Under the terms of the agreement, Deep Apple

根据协议条款，深层苹果公司

will

将要

discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.

利用其专有的药物发现平台，结合机器学习驱动的虚拟筛选与冷冻电子显微镜（cryo-EM）赋能的结构生物学，大幅提高先导化合物生成与优化的速度、质量和创新性。

Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.

诺和诺德将获得在全球范围内开发、生产及商业化这些化合物和产品在所有适应症中的独家权利。

Also Read:

另请阅读：

Novo Nordisk’s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say

欧洲监管机构表示，诺和诺德的Wegovy与罕见视力丧失疾病风险增加有关。

Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately before the start of IND-enabling studies.

两家公司将就研究计划进行合作，在新药临床试验（IND）前研究开始之前，项目将立即移交给诺和诺德。

Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk.

Deep Apple 有资格从诺和诺德获得预付款、研究费用和里程碑付款。

Deep Apple will be eligible to receive up to $812 million in payments and potential royalties on sales of any products that emerge from the collaboration.

Deep Apple 将有资格获得高达 8.12 亿美元的付款，以及因合作产生的任何产品销售的潜在版税。

Recently, the Danish pharma giant

近日，丹麦制药巨头

initiated

已启动

a Phase 3 trial to evaluate the efficacy and safety of cagrilintide sc combined with semaglutide sc (CagriSema sc) once weekly for weight management and long-term weight maintenance in obese participants.

一项评估每周一次皮下注射卡格列肽联合司美鲁肽（CagriSema 皮下注射）在肥胖参与者体重管理及长期体重维持中的疗效与安全性的3期临床试验。

The two-part study in around 600 participants will last about 3 years and 3 months.

这项针对约600名参与者、分为两部分的研究将持续3年3个月左右。

In March, Novo Nordisk announced headline results from the REDEFINE 2 phase 3 trial in the

今年3月，诺和诺德宣布了REDEFINE 2三期试验的初步结果。

global REDEFINE program

全局重新定义程序

。

REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema compared to placebo.

REDEFINE 2 是一项为期68周的疗效和安全性试验，研究每周一次皮下注射CagriSema与安慰剂的对比。

After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose.

68周后，接受CagriSema治疗的患者中有61.9%使用了最高剂量。

When evaluating treatment effects, if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% with placebo.

在评估治疗效果时，如果所有人都坚持治疗，接受CagriSema治疗的人在68周后体重减轻了15.7%，而安慰剂组为3.1%。

Last week,

上周，

Regeneron Pharmaceuticals, Inc.

再生元制药公司

REGN

再生元制药（Regeneron Pharmaceuticals）

released interim results from the ongoing Phase 2 COURAGE trial evaluating Regeneron’s trevogrumab (anti-GDF8/anti-myostatin) with semaglutide (GLP-1 receptor agonist) with or without garetosmab

发布了正在进行的2期COURAGE试验的中期结果，该试验评估了再生元公司的trevogrumab（抗GDF8/抗肌肉生长抑制素）与司美鲁肽（GLP-1受体激动剂）联合或不联合garetosmab的效果。

(anti-activin A) for obesity

（抗激活素A）用于肥胖症

。

The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to the loss of lean mass.

试验表明，大约35%的司美鲁肽减重效果是由于瘦体重的减少。

Price Action:

价格行为:

NVO stock is up 0.04% at $79.36 at the last check Wednesday.

NVO股票在周三最后一次检查时上涨了0.04%，达到79.36美元。

加载中...